Navigation Links
Proliferation in Medical Technology

Mutant Genes in High-Risk Childhood Leukemias Identified

... in the on position, triggering the uncontrolled proliferation of white blood cells that is seen in leukemia." ... of many kinases known to be components of the proliferation machinery of white blood cells. The team analyzed ... could switch them on to drive the blood cell proliferation that is characteristic of ALL," said Stephen ...

XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma

... malignancy characterized by the accumulation and proliferation of clonal plasma cells in the marrow, leading to ... of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their ... malignancy characterized by the accumulation and proliferation of clonal plasma cells in the marrow, leading to ...

Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2

... a wide range of cancers. CK2 drives the excessive proliferation phenotype of cancer cells through its ... drives key cell survival pathways and proliferation of cancer cells, but it has been notoriously ... is of central importance in driving cancer cell proliferation as well as in angiogenesis. As such, CX-4945 is ...

Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors

... and PI3K. SF2523 demonstrated potent anticancer proliferation activity across a broad range of 18 cancer ... and multiple myeloma). Notably, SF2523 inhibited proliferation in multiple cell lines with KRAS mutations, ... of new blood vessels for cancer growth), proliferation and metastasis. Semafore's innovative PI3K ...

Injection Reverses Heart-Attack Damage

... production of a cellular receptor for NRG1, known as ErbB4, cardiomyocyte proliferation was further enhanced, demonstrating that NRG1 works by stimulating this ... placed over the site of cardiac injury in rats, it induced cardiomyocyte proliferation and improved heart function ( Nature Medicine 2007; 13:962-9). Similar ...

Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients

... ATM and PIM-1. SF1126 is designed to inhibit both angiogenesis and cell proliferation by targeting and binding to integrins that are expressed on the surface of ... are important in controlling cell growth/angiogenesis, differentiation, proliferation and survival/apoptosis. Dysregulation of the PI3 kinase signaling ...

Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting

... ATM and PIM-1. SF1126 is designed to inhibit both angiogenesis and cell proliferation by targeting and binding to specific integrins that are expressed on the ... are important in controlling cell growth/angiogenesis, differentiation, proliferation and survival/apoptosis. Dysregulation of the PI3 kinase signaling ...

Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma

... inhibited by drug treatment in vitro. PCI-32765 also inhibited the proliferation of, and induced apoptosis in, multiple B-cell lymphoma cell lines in ... and other immune mediated diseases. The inhibition of B-cell function and proliferation in the various models, including lymphomas, forms the basis for our phase ...

Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents

... eluted in biodegradable polymers, are effective in reducing neointimal proliferation in comparison with bare metal stents. The nine month results of PAINT, ... stent system utilizes paclitaxel, which has been shown to reduce tissue proliferation in the coronary vessels following stent implantation, and is based upon ...

St. Jude Defines Eye Cancer Gene's Role in Retinal Development

... data, we propose that N-myc plays a central role in coordinating retinal proliferation with eye growth during development." Genes in the Myc family carry out ... the gene, the result is both a reduction in retinal progenitor cell proliferation and a reduction in the signaling cues that coordinate the growth of the ...

Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting

... investigational oral, non-peptide, platelet growth factor that induces the proliferation and differentiation of cells in the bone marrow to produce ... been shown in pre-clinical research and clinical trials to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give ...

Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314

... of Aurora kinases A, B and C. SNS-314 targets the uncontrolled cellular proliferation associated with cancer by halting cell division at the mitotic phase of ... involved in cancer cell division and have a central role in the abnormal proliferation of tumors. About Sunesis Pharmaceuticals Sunesis is a clinical-stage ...

Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis

... regulates calcium homeostasis and bone resorption by acting primarily on target cells in bone and kidney, whereas PTHrP and its analogs regulate cell proliferation and differentiation in developing tissues and appear to play an important role in regulating bone remodeling in adults. While both peptides have ...

Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer

... Genomic Grade is available to European oncologists and pathologists. The genomic grade test analyzes a set of 97 genes to precisely quantify the proliferation potential of the tumor, and has been validated in several studies, covering more than 2 800 tumor samples. MapQuantTM Genomic Grade contributes to ...

5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH

... glargine. Diabetic retinopathy is a major cause of blindness in patients with diabetes. It is a progressive disease that results from cellular proliferation within the eye. The stimulation of IGF1 receptors is involved in this process. In the study of patients with retinopathy, the progression of diabetic ...

Neurocrine Biosciences Presents Elagolix Data

... that transient inhibition of plasma testosterone and intra-prostatic androgens results in the reduction of prostate weight, a reduction in epithelial proliferation and suppression of prostate growth. If these preclinical results are replicated in men, daily transient inhibition of androgens with a GnRH ...

Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506

... targets along a spectrum of angiogenic pathways, including VEGFR and TIE2. BAY 73-4506 has also been shown in preclinical studies to prevent the proliferation of tumor cell lines while promoting apoptosis (cell death) by directly targeting several oncogenic TK receptors. The clinical significance of these ...

Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support

... nonmyeloablative conditioning therapy. Fate Therapeutics is developing FT1050 to improve the overall efficiency of HSC treatment by enhancing HSC proliferation and homing to the bone marrow. "The mission of Fate Therapeutics is to develop small molecules and biologics that modulate adult stem cells ...

Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers

... a patient's own cells directly at the wound site is believed to stimulate angiogenesis and granulation tissue formation through the recruitment and proliferation of cells such as monocytes, fibroblasts and endothelial cells. These cell types are critical for the effective stimulation of a variety of wound ...

Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting

... When the retina becomes separated from the retinal pigment epithelium (RPE) because a tear or hole occurs in the retina, many cell types undergo proliferation and consequently have the potential to form retinal scars. When such cell types are present in the space between the retina and the RPE, subretinal ...

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis

... a treatment for patients with relapsing forms of multiple sclerosis (MS). Cladribine is a small molecule that may interfere with the behavior and the proliferation of certain white blood cells, particularly lymphocytes, which are thought to be involved in the pathological process of MS. The clinical ...

Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint

... and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) - two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, ...

SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production

... and indefinite cell proliferation. The EB66 cell line also provides key qualities for industrial applications, including growth in serum-free medium, proliferation in bioreactors at high cell densities such as suspension cells, and demonstrates high susceptibility to a broad range of genetically engineered and ...

Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy

... a model of glomerulonephritis, CCL2-LPM significantly decreased the influx of leukocytes into the kidney and resulted in less kidney mesangial cell proliferation and fibrosis. In preclinical testing, CCL2-LPM demonstrated no adverse effects at doses up to 1.5 mg/kg every other day for 15 doses. About IgA ...

Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years

... supplied to Boston Scientific as part of a distribution agreement between the two companies. Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent ...

Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack

... biological properties of IGF-1 protein include the inhibition of programmed cell death or apoptosis, adaptive cardiomyocyte hypertrophy, proliferation of cardiac progenitor cells and angiogenesis. These observations provide a strong scientific rationale for the clinical development of an IGF-1 based ...

Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial

... important safety and effectiveness information, is available online at www.xiencev.com . Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent ...

The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent

... important safety and effectiveness information, is available online at www.xiencev.com . Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent ...

Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer

... first identified miR-191, a microRNA that is abnormally over-expressed in human liver cancer cells, and which when inhibited effectively reduces cell proliferation and promotes cell-death of these liver tumor cells. The scientists then used an in-vivo model called Orthotopic Xenograft, in which an artificial ...

EntreMed Presents Initial Clinical Results for ENMD-2076

... antitumor activity observed with the combination of ENMD-2076 and cisplatin, over either agent alone, is correlated to biomarkers of angiogenesis, proliferation and apoptosis. These results provide a rationale for the clinical evaluation of ENMD-2076 in tumors responsive to platinum compounds, and ...

Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent

... supplied to Boston Scientific as part of a distribution agreement between the two companies. Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit ...

Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months

... http://www.zevalin.com for more information. About Non-Hodgkin's Lymphoma Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be broadly ...

Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology

... December 23, 2008. About Acute Myeloid Leukemia AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and ...

TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients

... company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis) and inflammation. Edema, angiogenesis and inflammation are involved in the pathology of many major human diseases. TargeGen initiated ...

Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH

... 23, 2008. About Acute Myeloid Leukemia AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and ...

FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder

... PROMACTA is an oral, non-peptide thrombopoietin receptor agonist that has been shown in pre-clinical research and clinical trials to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give rise to blood platelets. PROMACTA was discovered as a result of a research ...

Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint

... without a loss in anti-tumor or immunomodulatory activities. About Non-Hodgkin's Lymphoma Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be ...

Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma

... can visit http://www.zevalin.com for more information. About Non-Hodgkin's Lymphoma Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be ...

Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium

... and hematologic tumor types. About Acute Myeloid Leukemia AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and ...

Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial

... without a loss in anti-tumor or immunomodulatory activities. About Non-Hodgkin's Lymphoma Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be ...
Other Contents
(Date:7/22/2014)... researchers in modifying properties of nanomaterials for application in ... to recent innovative studies conducted by scientists from the ... of a simple, efficient and low cost technique involving ... by Professor Sow Chorng Haur from the Department of ... the properties of two different types of materials can ...
(Date:7/22/2014)... Stem cells offer much promise for treating damaged organs ... survival is poor, limiting their effectiveness. New methods are ... optimize their therapeutic function after transplantation, as described in ... a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ... Open Access website . , In ...
(Date:7/22/2014)... DURHAM, N.C. In a cost-effectiveness analysis of commercial ... the drug Qsymia showed the best value for the ... loss, but was also the most expensive option tested, ... Graduate Medical School. , The findings, published in the ... important information on the health and weight-loss benefits per ...
Breaking Biology News(10 mins):NUS scientists use low cost technique to improve properties and functions of nanomaterials 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 3Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3
(Date:7/22/2014)... (PRWEB) July 22, 2014 As part ... School of Medicine at Mount Sinai have helped identify ... the risk of developing schizophrenia, in the largest genomic ... with 80,000 people. The findings, published online in Nature, ... schizophrenia, and could lead to new approaches to treating ...
(Date:7/22/2014)... Alan Mozes HealthDay Reporter ... used to treat moderate-to-severe allergic asthma appears to offer relief ... standard medications, new research suggests. The prescription drug -- ... U.S. Food and Drug Administration approval earlier this year for ... is taken at a high dose for a six-month period ...
(Date:7/22/2014)... team has identified protein "signatures" of genetic mutations ... cause of cancer deaths after lung cancer. , ... current issue of the journal Nature ... cancer, "will enable new advances" in diagnosing and ... a first-of-its-kind paper. I think it,s a very ...
(Date:7/22/2014)... 2014 The “Human Insulin Market ... Acting, Premixed), Modern Human Insulin (Rapid Acting, Long ... Novomix, Tresiba, Others) - Forecast to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ... estimates and forecasts of the revenue and share ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 For more ... and cold storage consumers with dynamic, specialized ... and customer satisfaction. Offering 50-70% less energy requirements ... process. This process is completed through a non-chemical ... technologies also provide a 4.2 Micron droplet. The ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 2Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 3Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 4Health News:Asthma Drug May Help Those With Chronic Hives 2Health News:Asthma Drug May Help Those With Chronic Hives 3Health News:Vanderbilt discovery may advance colorectal cancer diagnosis and treatment 2Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 5Health News:Smart Fog Inc Announces Cold Storage Humidification Technology to be Exhibited at the 2014 Fresh Summit Convention & Expo 2Health News:Smart Fog Inc Announces Cold Storage Humidification Technology to be Exhibited at the 2014 Fresh Summit Convention & Expo 3
Other TagsOther Tags